Table 4.
Comparison of indicators in the use of rhTPO for treatment of grade II and III thrombocytopenia [n, (%)].
| Indicators | Use of recombinant human thrombopoietin (rhTPO) | Z/χ2 value | P Value | |
|---|---|---|---|---|
| Grade II (n = 100) | Grade III (n = 94) | |||
| Days of treatment | 5.00 (3.00, 6.00) | 6.00 (4.00, 8.00) | −3.610 | <0.001 |
| Time to increase platelets (days) | 3.00 (2.00, 5.00) | 5.50 (3.00, 8.00) | −4.977 | <0.001 |
| Delay of the next chemoradiotherapy cycle (days) | 0 (0, 5.75) | 3.00 (0, 9.25) | −2.602 | 0.009 |
| Prolonged hospitalization due to platelet decline (days) | 1.00 (0, 6.00) | 3.50 (0, 7.00) | −1.821 | 0.069 |
| Increased hospitalization costs due to platelet decline | 5040.00 (3024.00, 6979.00) | 6503.00 (5040.00, 9474.00) | −4.900 | <0.001 |
| Platelet transfusion | ||||
| No | 95 (95.0) | 67 (71.3) | 19.798 | <0.001 |
| Yes | 5 (5.0) | 27 (28.7) | ||